Quarterly report [Sections 13 or 15(d)]

Consolidated Statements of Cash Flows

v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Feb. 28, 2025
Feb. 29, 2024
Feb. 28, 2025
Feb. 29, 2024
Cash flows from operating activities:        
Net income (loss) $ (4,758) $ (11,920) $ 9,701 $ (33,054)
Adjustments to reconcile net income (loss) to net cash used in operating activities:        
Depreciation     14 25
Amortization of debt issuance costs   203   572
Issuance costs for private placement of shares and warrants through placement agent       906
Amortization of discount on convertible notes 110 409 348 951
Gain on restructuring of payables (327)   (407)  
Loss on derivatives     852 971
Loss on induced conversion   3,353 1,180 5,993
Loss on note extinguishment   1,550   6,040
Stock-based compensation     1,013 1,944
Changes in operating assets and liabilities:        
Prepaid expenses and other assets     (3,483) (28)
Accounts payable, accrued expenses, and other liabilities     (12,320) 6,348
Net cash provided by operating activities     (3,102) (9,332)
Cash flows from investing activities:        
Net cash provided by/used in investing activities    
Cash flows from financing activities:        
Proceeds from warrant transactions, net of offering costs     10,377  
Proceeds from sale of common stock and warrants, net of issuance costs       5,696
Proceeds from warrant exercises       300
Proceeds from convertible note and warrant issuances, net of offering costs       2,011
Cash paid for note payable     (710)  
Proceeds from exercise of stock options     21  
Proceeds held in trust       300
Net cash provided by financing activities     9,688 8,307
Net change in cash and restricted cash     6,586 (1,025)
Cash, cash equivalents, and restricted cash at beginning of period     9,814 9,048
Cash, cash equivalents, and restricted cash at end of period 16,400 8,023 16,400 8,023
Cash, cash equivalents, and restricted cash consisted of the following:        
Cash and cash equivalents 16,400 1,404 16,400 1,404
Restricted cash 0 6,619 0 6,619
Total cash, cash equivalents, and restricted cash $ 16,400 $ 8,023 16,400 8,023
Supplemental disclosure:        
Cash paid for interest     25 44
Non-cash investing and financing transactions:        
Derivative liability associated with warrants       102
Issuance of common stock for principal of convertible notes     2,593 4,750
Accrued dividends on Series C and D convertible preferred stock     $ 1,106 1,110
Warrants issued to placement agent       413
Note conversion to common stock and warrants       $ 3,302